Innovation in analytical tool development across the mRNA vaccine & AAV gene therapy spaces

Cell & Gene Therapy Insights 2022; 8(8), 1065–1069

DOI: 10.18609/cgti.2022.157

Published: 21 September 2022
Lawrence Thompson

Lawrence Thompson, PhD is an Associate Research Fellow & Group Leader in Analytical R&D within Biotherapeutic Pharmaceutical Sciences at Pfizer. He has been with Pfizer for more than 8 years and is a CMC analytical SME for Pfizer’s adenoviral & plasmid DNA based immunotherapeutic, mRNA vaccine drug substance and nucleic acid starting material pipeline (used for both rAAV gene therapy & mRNA vaccine). Prior to joining Pfizer, he spent 3 years in small biotech at two different companies as lead scientist in the development of serum-based cancer diagnostics. He received his PhD in Biochemistry from Vanderbilt University and did his post-doctoral work at the University of Tennessee. His work has generated a number of peer reviewed publications and presentations at scientific conferences as well as internally within Pfizer